Institut Pasteur-TheraVectys Joint Lab, Université Paris Cité, 28 rue du Dr. Roux, 75015 Paris, France.
Institut Pasteur, Integrated Mycobacterial Pathogenomics Unit, CNRS UMR 3525, Université Paris Cité, 25 rue du Dr. Roux, 75015 Paris, France.
Cell Rep. 2022 Jul 26;40(4):111142. doi: 10.1016/j.celrep.2022.111142.
Lentiviral vectors (LVs) are highly efficient at inducing CD8 T cell responses. However, LV-encoded antigens are processed inside the cytosol of antigen-presenting cells, which does not directly communicate with the endosomal major histocompatibility complex class II (MHC-II) presentation pathway. LVs are thus poor at inducing CD4 T cell response. To overcome this limitation, we devised a strategy whereby LV-encoded antigens are extended at their N-terminal end with the MHC-II-associated light invariant chain (li), which contains an endosome-targeting signal sequence. When evaluated with an LV-encoded polyantigen composed of CD4 T cell targets from Mycobacterium tuberculosis, intranasal vaccination in mice triggers pulmonary polyfunctional CD4 and CD8 T cell responses. Adjuvantation of these LVs extends the mucosal immunity to Th17 and Tc17 responses. A systemic prime and an intranasal boost with one of these LV induces protection against M. tuberculosis. This strategy improves the protective power of LVs against infections and cancers, where CD4 T cell immunity plays an important role.
慢病毒载体 (LVs) 非常有效地诱导 CD8 T 细胞反应。然而,LV 编码的抗原在抗原呈递细胞的细胞质中被加工,这与内体主要组织相容性复合体 II (MHC-II) 呈递途径没有直接通讯。因此,LV 诱导 CD4 T 细胞反应的能力较差。为了克服这一限制,我们设计了一种策略,即在 LV 编码的抗原的 N 末端延长与 MHC-II 相关的轻链不变链 (li),其中包含一个内体靶向信号序列。当用包含结核分枝杆菌 CD4 T 细胞靶标的 LV 编码多抗原进行评估时,鼻腔内接种疫苗可在小鼠中引发肺部多效性 CD4 和 CD8 T 细胞反应。这些 LV 的佐剂作用将粘膜免疫扩展至 Th17 和 Tc17 反应。用其中一种 LV 进行全身初次免疫和鼻腔内加强免疫可诱导对结核分枝杆菌的保护。该策略提高了 LVs 在感染和癌症中的保护能力,其中 CD4 T 细胞免疫发挥着重要作用。